Bispecific Antibodies
Title | Bispecific Antibodies PDF eBook |
Author | Roland E. Kontermann |
Publisher | Springer Science & Business Media |
Total Pages | 381 |
Release | 2011-07-21 |
Genre | Medical |
ISBN | 3642209106 |
The concept of using bispecific antibodies for cancer therapy by retargeting immune effector cells was developed several years ago. Initial clinical studies were rather disappointing mainly due to low efficacy, severe side effects and the immunogenicity of the bispecific antibodies. The progress in antibody engineering finally led to the generation of new classes of bispecific antibodies lacking these obstacles. In addition, new applications were established, such as pre-targeting strategies in radioimmunotherapy and dual targeting approaches in order to improve binding, selectivity and efficacy. In this book, the different ways of generating bispecific antibodies are described, with emphasis on recombinant formats. The various applications of bispecific antibodies, e.g. in cellular cancer immunotherapy, radioimmunotherapy and pretargeting strategies are covered, and emerging applications such as dual targeting strategies, which involve the simultaneous inhibition of two targets, are addressed.
Bispecific Antibodies for T-Cell Based Immunotherapy
Title | Bispecific Antibodies for T-Cell Based Immunotherapy PDF eBook |
Author | Brian H. Santich |
Publisher | Frontiers Media SA |
Total Pages | 97 |
Release | 2021-01-21 |
Genre | Medical |
ISBN | 2889664155 |
CK is affiliated with the Roche Innovation Center Zurich, holds stocks and has patents with Hoffmann-La Roche company. NKC reports receiving commercial research grants from Y-mabs Therapeutics and Abpro-Labs Inc.; holding ownership interest/equity/options in Y-Mabs Therapeutics Inc., and in Abpro-Labs, and owning stock options in Eureka Therapeutics. NKC is the inventor of pending and issued patents filed by MSK, including hu3F8 and 8H9 licensed to Ymabs Therapeutics, beta-glucan to Biotec Pharmacon, and HER2 bispecific antibody to Abpro-labs. NKC is an advisory board member for Abpro-Labs and Eureka Therapeutics
Innovations for Next-Generation Antibody-Drug Conjugates
Title | Innovations for Next-Generation Antibody-Drug Conjugates PDF eBook |
Author | Marc Damelin |
Publisher | Springer |
Total Pages | 357 |
Release | 2018-05-29 |
Genre | Medical |
ISBN | 3319781545 |
Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.
Approaches to the Purification, Analysis and Characterization of Antibody-Based Therapeutics
Title | Approaches to the Purification, Analysis and Characterization of Antibody-Based Therapeutics PDF eBook |
Author | Allan Matte |
Publisher | Elsevier |
Total Pages | 222 |
Release | 2020-09-07 |
Genre | Business & Economics |
ISBN | 0081030193 |
Approaches to the Purification, Analysis and Characterization of Antibody-Based Therapeutics provides the interested and informed reader with an overview of current approaches, strategies and considerations relating to the purification, analytics and characterization of therapeutic antibodies and related molecules. While there are obviously other books published in and around this subject area, they seem to be either older (c.a. year 2000 publication date) or are more limited in scope. The book will include an extensive bibliography of the published literature in the respective areas covered. It is not, however, intended to be a how-to methods book. Covers the vital new area of R&D on therapeutic antibodies Written by leading scientists and researchers Up-to-date coverage and includes a detailed bibliography
Bispecific Antibodies
Title | Bispecific Antibodies PDF eBook |
Author | Roland E. Kontermann |
Publisher | |
Total Pages | 392 |
Release | 2011-08-31 |
Genre | |
ISBN | 9783642209116 |
Process Scale Purification of Antibodies
Title | Process Scale Purification of Antibodies PDF eBook |
Author | Uwe Gottschalk |
Publisher | John Wiley & Sons |
Total Pages | 752 |
Release | 2017-03-07 |
Genre | Medical |
ISBN | 1119126932 |
Promoting a continued and much-needed renaissance in biopharmaceutical manufacturing, this book covers the different strategies and assembles top-tier technology experts to address the challenges of antibody purification. • Updates existing topics and adds new ones that include purification of antibodies produced in novel production systems, novel separation technologies, novel antibody formats and alternative scaffolds, and strategies for ton-scale manufacturing • Presents new and updated discussions of different purification technologies, focusing on how they can address the capacity crunch in antibody purification • Emphasizes antibodies and innovative chromatography methods for processing
Bispecific Antibodies
Title | Bispecific Antibodies PDF eBook |
Author | Michael W. Fanger |
Publisher | Springer |
Total Pages | 151 |
Release | 1995-01-01 |
Genre | Antibody-drug conjugates |
ISBN | 9783540588856 |
Murine, human, and chimeric monoclonal antibodies (mAB) are currently being used for the treatment of a variety of human disorders including cancer. Bispecific antibodies (BsAB) have been developed as reagents that may permit even more specific linkages and mediate more efficient and appropriate bridges than mAB. The volume contains eight chapters: the production of BsAB; T cell-targeted cytotoxicity; myeloid cell-targeted cytotoxicity of tumor cells; natural killer cell-directed BsAB; targeted cytotoxicity of infectious agents and infectious cells; targeting drugs, toxins, and radionuclides with BsAB; targeting immune complexes and enzymes to cell surface receptors; and antigen targeting. Annotation copyright by Book News, Inc., Portland, OR